Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-assisted OCT biomarker study in diabetic macular edema comparing dexamethasone implant with anti-VEGF
NL-OMON58164Phase 4Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexamethasone in diabetic macular edema (DME) (3 arms), sponsored by AbbVie Inc. Planned start Jan 2026; status: withdrawn.
02
Drugs
dexamethasone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON58164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58164.